{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:45:42Z","timestamp":1792842342906,"version":"4.5.0"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Research Foundation funded","award":["NRF-2021RIA5A2031612"],"award-info":[{"award-number":["NRF-2021RIA5A2031612"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Development of validated biomarkers to detect early Alzheimer disease (AD) neuropathology is needed for therapeutic AD trials. Abnormal concentrations of \u201ccore\u201d AD biomarkers, cerebrospinal fluid (CSF) amyloid beta1\u201342, total tau, and phosphorylated tau correlate well with neuroimaging biomarkers and autopsy findings. Nevertheless, given the limitations of established CSF and neuroimaging biomarkers, accelerated development of blood-based AD biomarkers is underway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>Here we describe the clinical significance of CSF and plasma AD biomarkers to detect disease pathology throughout the Alzheimer continuum and correlate with imaging biomarkers. Use of the AT(N) classification by CSF and imaging biomarkers provides a more objective biologically based diagnosis of AD than clinical diagnosis alone. Significant progress in measuring CSF AD biomarkers using extensively validated highly automated assay systems has facilitated their transition from research use only to approved in vitro diagnostics tests for clinical use. We summarize development of plasma AD biomarkers as screening tools for enrollment and monitoring participants in therapeutic trials and ultimately in clinical care. Finally, we discuss the challenges for AD biomarkers use in clinical trials and precision medicine, emphasizing the possible ethnocultural differences in the levels of AD biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>CSF AD biomarker measurements using fully automated analytical platforms is possible. Building on this experience, validated blood-based biomarker tests are being implemented on highly automated immunoassay and mass spectrometry platforms. The progress made developing analytically and clinically validated plasma AD biomarkers within the AT(N) classification scheme can accelerate use of AD biomarkers in therapeutic trials and routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/clinchem\/hvad139","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T16:33:20Z","timestamp":1693499600000},"page":"1247-1259","source":"Crossref","is-referenced-by-count":66,"title":["Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology"],"prefix":"10.1093","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5235-8993","authenticated-orcid":false,"given":"Ju Hee","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Research Center for Controlling Intercellular Communication, Inha University , Incheon , South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Korecka","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-1180","authenticated-orcid":false,"given":"Edward B","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-2766","authenticated-orcid":false,"given":"Katheryn A Q","family":"Cousins","sequence":"additional","affiliation":[{"name":"Department of Neurology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-1496","authenticated-orcid":false,"given":"Thomas F","family":"Tropea","sequence":"additional","affiliation":[{"name":"Department of Neurology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice A","family":"Chen-Plotkin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-5098","authenticated-orcid":false,"given":"David J","family":"Irwin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wolk","sequence":"additional","affiliation":[{"name":"Department of Neurology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Brylska","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie M","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"2023110702161334700_hvad139-B1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"key":"2023110702161334700_hvad139-B2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects","volume":"65","author":"Shaw","year":"2009","journal-title":"Ann Neurol"},{"key":"2023110702161334700_hvad139-B5","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.jalz.2013.05.1769","article-title":"The Alzheimer\u2019s Disease Neuroimaging Initiative: a review of papers published since its inception","volume":"9","author":"Weiner","year":"2013","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B6","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jalz.2018.05.008","article-title":"The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer\u2019s disease diagnosis: A review","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B7","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/alz.12510","article-title":"Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease-related blood-based biomarkers: results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group","volume":"18","author":"Verberk","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","article-title":"Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1\u201342) in human cerebrospinal fluid","volume":"12","author":"Bittner","year":"2016","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B9","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","article-title":"Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment","volume":"74","author":"Janelidze","year":"2017","journal-title":"JAMA Neurol"},{"key":"2023110702161334700_hvad139-B10","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/alz.12751","article-title":"An accurate fully automated panel of plasma biomarkers for Alzheimer\u2019s disease","volume":"19","author":"Palmqvist","year":"2023","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(00)03589-3","article-title":"Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology group of the medical research council cognitive function and ageing study (MRC CFAS)","volume":"357","author":"Neuropathology Group. Medical Research Council Cognitive Function and Aging Study","year":"2001","journal-title":"Lancet"},{"key":"2023110702161334700_hvad139-B12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"2023110702161334700_hvad139-B13","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.0b013e3181dd4dd8","article-title":"CSF Biomarkers predict a more malignant outcome in Alzheimer disease","volume":"74","author":"Wallin","year":"2010","journal-title":"Neurology"},{"key":"2023110702161334700_hvad139-B14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","article-title":"CSF Biomarker variability in the Alzheimer\u2019s association quality control program","volume":"9","author":"Mattsson","year":"2013","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1373\/clinchem.2013.220392","article-title":"Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid","volume":"60","author":"Leinenbach","year":"2014","journal-title":"Clin Chem"},{"key":"2023110702161334700_hvad139-B16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jalz.2015.06.1890","article-title":"Round robin test on quantification of amyloid-beta 1\u201342 in cerebrospinal fluid by mass spectrometry","volume":"12","author":"Pannee","year":"2016","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2016.05.014","article-title":"CSF Abeta1\u201342\u2014an excellent but complicated Alzheimer\u2019s biomarker\u2014a route to standardisation","volume":"467","author":"Kuhlmann","year":"2017","journal-title":"Clin Chim Acta"},{"key":"2023110702161334700_hvad139-B18","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/alz.12145","article-title":"First amyloid beta1\u201342 certified reference material for re-calibrating commercial immunoassays","volume":"16","author":"Boulo","year":"2020","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B19","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1515\/cclm-2015-0733","article-title":"Assessing the commutability of reference material formats for the harmonization of amyloid-beta measurements","volume":"54","author":"Bjerke","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2023110702161334700_hvad139-B20","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF Biomarkers of Alzheimer\u2019s disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B21","doi-asserted-by":"crossref","first-page":"91.","DOI":"10.1186\/s13195-019-0550-8","article-title":"Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer\u2019s disease","volume":"11","author":"Leitao","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"2023110702161334700_hvad139-B22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/joim.12816","article-title":"Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future","volume":"284","author":"Blennow","year":"2018","journal-title":"J Intern Med"},{"issue":"Pt 3","key":"2023110702161334700_hvad139-B23","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/brain\/awu367","article-title":"Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer\u2019s disease","volume":"138","author":"Mattsson","year":"2015","journal-title":"Brain"},{"key":"2023110702161334700_hvad139-B24","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","article-title":"Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease","volume":"85","author":"Palmqvist","year":"2015","journal-title":"Neurology"},{"key":"2023110702161334700_hvad139-B25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/acn3.81","article-title":"Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer\u2019s disease","volume":"1","author":"Mattsson","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"2023110702161334700_hvad139-B26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol"},{"key":"2023110702161334700_hvad139-B27","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer\u2019s disease: towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol"},{"key":"2023110702161334700_hvad139-B28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3233\/JAD-170927","article-title":"Added diagnostic value of cerebrospinal fluid biomarkers for differential dementia diagnosis in an autopsy-confirmed cohort","volume":"63","author":"Niemantsverdriet","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2023110702161334700_hvad139-B29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3233\/JAD-141725","article-title":"Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer\u2019s disease from other dementias and healthy controls in the OPTIMA cohort","volume":"44","author":"Seeburger","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"2023110702161334700_hvad139-B30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","article-title":"Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: a follow-up study","volume":"5","author":"Hansson","year":"2006","journal-title":"Lancet Neurol"},{"key":"2023110702161334700_hvad139-B31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archgenpsychiatry.2011.155","article-title":"Cerebrospinal fluid levels of beta-amyloid 1\u201342, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia","volume":"69","author":"Buchhave","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"2023110702161334700_hvad139-B32","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010","volume":"71","author":"Beach","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"2023110702161334700_hvad139-B33","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","article-title":"Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography","volume":"71","author":"Palmqvist","year":"2014","journal-title":"JAMA Neurol"},{"key":"2023110702161334700_hvad139-B34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jalz.2015.12.007","article-title":"Inequalities in dementia incidence between six racial and ethnic groups over 14 years","volume":"12","author":"Mayeda","year":"2016","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2018.09.009","article-title":"Perspectives on ethnic and racial disparities in Alzheimer\u2019s disease and related dementias: update and areas of immediate need","volume":"15","author":"Babulal","year":"2019","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/jamaneurol.2018.4249","article-title":"Assessment of racial disparities in biomarkers for Alzheimer disease","volume":"76","author":"Morris","year":"2019","journal-title":"JAMA Neurol"},{"key":"2023110702161334700_hvad139-B37","doi-asserted-by":"crossref","first-page":"e1917363","DOI":"10.1001\/jamanetworkopen.2019.17363","article-title":"Racial disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment","volume":"2","author":"Garrett","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2023110702161334700_hvad139-B38","doi-asserted-by":"crossref","first-page":"e2235068","DOI":"10.1001\/jamanetworkopen.2022.35068","article-title":"Association of plasma and cerebrospinal fluid Alzheimer disease biomarkers with race and the role of genetic ancestry, vascular comorbidities, and neighborhood factors","volume":"5","author":"Hajjar","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023110702161334700_hvad139-B39","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1212\/NXG.0000000000000571","article-title":"African Americans have differences in CSF soluble TREM2 and associated genetic variants","volume":"7","author":"Schindler","year":"2021","journal-title":"Neurol Genet"},{"key":"2023110702161334700_hvad139-B40","doi-asserted-by":"crossref","first-page":"e12102","DOI":"10.1002\/trc2.12102","article-title":"Evaluating the Alzheimer\u2019s disease data landscape","volume":"6","author":"Birkenbihl","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"2023110702161334700_hvad139-B41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/alz.12797","article-title":"Increasing participant diversity in AD research: plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer\u2019s Disease Neuroimaging Initiative 4","volume":"19","author":"Weiner","year":"2023","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B42","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","article-title":"Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility","volume":"18","author":"Karikari","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"2023110702161334700_hvad139-B43","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","article-title":"Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative","volume":"26","author":"Karikari","year":"2021","journal-title":"Mol Psychiatry"},{"key":"2023110702161334700_hvad139-B44","first-page":"434","article-title":"Population-based blood screening for preclinical Alzheimer\u2019s disease in a British birth cohort at age 70","volume":"144","author":"Keshavan","year":"2021","journal-title":"Brain"},{"key":"2023110702161334700_hvad139-B45","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/archneurol.2011.1841","article-title":"Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis","volume":"69","author":"Koyama","year":"2012","journal-title":"Arch Neurol"},{"key":"2023110702161334700_hvad139-B46","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci Rep"},{"key":"2023110702161334700_hvad139-B47","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","article-title":"Plasma tau in Alzheimer disease","volume":"87","author":"Mattsson","year":"2016","journal-title":"Neurology"},{"key":"2023110702161334700_hvad139-B48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jalz.2012.01.001","article-title":"Improved protocol for measurement of plasma beta-amyloid in longitudinal evaluation of Alzheimer\u2019s Disease Neuroimaging Initiative study patients","volume":"8","author":"Figurski","year":"2012","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B49","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jalz.2018.01.004","article-title":"Plasma amyloid levels within the Alzheimer\u2019s process and correlations with central biomarkers","volume":"14","author":"Hanon","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B50","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B51","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"2023110702161334700_hvad139-B52","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/alz.12395","article-title":"Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma Abeta42\/Abeta40 and p-tau","volume":"18","author":"Janelidze","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13195-020-00728-w","article-title":"Comparison of ELISA- and SIMOA-based quantification of plasma Abeta ratios for early detection of cerebral amyloidosis","volume":"12","author":"De Meyer","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"2023110702161334700_hvad139-B54","doi-asserted-by":"crossref","first-page":"e1580","DOI":"10.1212\/WNL.0000000000009240","article-title":"Total Abeta(42)\/Abeta(40) ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis","volume":"94","author":"Doecke","year":"2020","journal-title":"Neurology"},{"key":"2023110702161334700_hvad139-B55","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JAD-140771","article-title":"Amyloid-beta 42\/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer\u2019s disease: validation of two novel assays","volume":"43","author":"Lewczuk","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"2023110702161334700_hvad139-B56","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1471-4159.2006.04404.x","article-title":"Amyloid beta peptide ratio 42\/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load","volume":"101","author":"Wiltfang","year":"2007","journal-title":"J Neurochem"},{"key":"2023110702161334700_hvad139-B57","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.25334","article-title":"Plasma amyloid as prescreener for the earliest Alzheimer pathological changes","volume":"84","author":"Verberk","year":"2018","journal-title":"Ann Neurol"},{"key":"2023110702161334700_hvad139-B58","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature23002","article-title":"Cryo-EM structures of tau filaments from Alzheimer\u2019s disease","volume":"547","author":"Fitzpatrick","year":"2017","journal-title":"Nature"},{"key":"2023110702161334700_hvad139-B59","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cca.2022.03.018","article-title":"P-tau217 in Alzheimer\u2019s disease","volume":"531","author":"Telser","year":"2022","journal-title":"Clin Chim Acta"},{"key":"2023110702161334700_hvad139-B60","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B61","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","article-title":"Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231","volume":"13","author":"Bayoumy","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"2023110702161334700_hvad139-B62","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"key":"2023110702161334700_hvad139-B63","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1212\/WNL.0000000000200358","article-title":"Effect of race on prediction of brain amyloidosis by plasma Abeta42\/Abeta40, phosphorylated tau, and neurofilament light","volume":"99","author":"Schindler","year":"2022","journal-title":"Neurology"},{"key":"2023110702161334700_hvad139-B64","doi-asserted-by":"crossref","first-page":"e20200861","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease","volume":"217","author":"Barthelemy","year":"2020","journal-title":"J Exp Med"},{"key":"2023110702161334700_hvad139-B65","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/alz.12236","article-title":"Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer\u2019s disease diagnosis","volume":"17","author":"Karikari","year":"2021","journal-title":"Alzheimers Dement"},{"key":"2023110702161334700_hvad139-B66","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","article-title":"Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia","volume":"87","author":"Rohrer","year":"2016","journal-title":"Neurology"},{"key":"2023110702161334700_hvad139-B67","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol"},{"key":"2023110702161334700_hvad139-B68","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","article-title":"Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease","volume":"10","author":"Lewczuk","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"2023110702161334700_hvad139-B69","doi-asserted-by":"crossref","first-page":"e1390","DOI":"10.1212\/WNL.0000000000006318","article-title":"Serum neurofilament light chain in behavioral variant frontotemporal dementia","volume":"91","author":"Steinacker","year":"2018","journal-title":"Neurology"},{"key":"2023110702161334700_hvad139-B70","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat Med"},{"key":"2023110702161334700_hvad139-B71","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"2023110702161334700_hvad139-B72","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","article-title":"Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the mayo clinic study on aging","volume":"74","author":"Mielke","year":"2017","journal-title":"JAMA Neurol"},{"key":"2023110702161334700_hvad139-B73","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/brain\/awy347","article-title":"Plasma tau\/amyloid-beta1\u201342 ratio predicts brain tau deposition and neurodegeneration in Alzheimer\u2019s disease","volume":"142","author":"Park","year":"2019","journal-title":"Brain"},{"key":"2023110702161334700_hvad139-B74","doi-asserted-by":"crossref","first-page":"848180","DOI":"10.3389\/fnagi.2022.848180","article-title":"Microglial activation, tau pathology, and neurodegeneration biomarkers predict longitudinal cognitive decline in Alzheimer\u2019s disease continuum","volume":"14","author":"Chen","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"2023110702161334700_hvad139-B75","doi-asserted-by":"crossref","first-page":"e2944-55.","DOI":"10.1212\/WNL.0000000000012109","article-title":"Astrocyte biomarkers in Alzheimer disease: A systematic review and meta-analysis","volume":"96","author":"Bellaver","year":"2021","journal-title":"Neurology"},{"key":"2023110702161334700_hvad139-B76","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-beta but not tau pathology in Alzheimer\u2019s disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"2023110702161334700_hvad139-B77","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00259-021-05258-7","article-title":"2020 Update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework","volume":"48","author":"Leuzy","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2023110702161334700_hvad139-B78","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","article-title":"Biomarkers for Alzheimer\u2019s disease-preparing for a new era of disease-modifying therapies","volume":"26","author":"Zetterberg","year":"2021","journal-title":"Mol Psychiatry"},{"key":"2023110702161334700_hvad139-B79","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"2023110702161334700_hvad139-B80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"2023110702161334700_hvad139-B81","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaneurol.2021.4654","article-title":"Biomarker-based prediction of longitudinal tau positron emission tomography in Alzheimer disease","volume":"79","author":"Leuzy","year":"2022","journal-title":"JAMA Neurol"},{"key":"2023110702161334700_hvad139-B82","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/69\/11\/1247\/52726623\/hvad139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/69\/11\/1247\/52726623\/hvad139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T21:18:42Z","timestamp":1699305522000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/69\/11\/1247\/7277360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":82,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,9,19]]},"published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvad139","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,9,19]]}}}